Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CENTENE CORPCNC · Entity 3133 | Director | July 28, 2026 | July 28, 2026 |
| DAVITA INC.DVA · Entity 3482 | Director | May 15, 2023 | May 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CENTENE CORP
Report date July 28, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,771 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 2,771 · Balance 2,771 F1: This award includes 2,771 shares of restricted stock units which will vest in full on the date of the Registrant's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This award includes 2,771 shares of restricted stock units which will vest in full on the date of the Registrant's 2027 annual meeting of stockholders.
DAVITA INC.
Report date May 15, 2023 · Filed May 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,069 |
Reported balance
After 2023-05-15 transaction · row 1
1 source rowRow 1 · 2023-05-15 · Grant · Acquired 516 · Balance 16,069 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
KINDRED HEALTHCARE, INC
Report date July 02, 2018 · Filed July 02, 2018
Section 16 reporting ended · disclosed 2018-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-07-02 transaction · row 1
1 source rowRow 1 · 2018-07-02 · Disposition to issuer · Disposed 424,340 · Balance 0 |
MYRIAD GENETICS INC
Report date April 30, 2025 · Filed April 30, 2025
Section 16 reporting ended · disclosed 2025-04-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 891,844 |
Reported balance
Holding disclosure · report date 2025-04-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 891,844 |
| Time-Based Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-08-13 | Direct | 342,040 |
Reported balance
Holding disclosure · report date 2025-04-30 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 342,040 |
| Performance-Based Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-08-13 | Direct | 339,088 |
Reported balance
Holding disclosure · report date 2025-04-30 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 339,088 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 28, 2026 20:34 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 2,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001071739-26-000158 · wk-form4_1785270838.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,771 F1 · shares: This award includes 2,771 shares of restricted stock units which will vest in full on the date of the Registrant's 2027 annual meeting of stockholders. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 26,827 | $9.98 | $267,733.46 |
DisclosureSEC source: 0001628280-25-014723 · wk-form4_1742933780.xml · nonDerivative · entry 4 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 891,844 F4 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 18,312 | $9.98 | $182,753.76 |
DisclosureSEC source: 0001628280-25-014723 · wk-form4_1742933780.xml · nonDerivative · entry 3 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 918,671 F3 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 52,682 | $10.01 | $527,346.82 |
DisclosureSEC source: 0001628280-25-014723 · wk-form4_1742933780.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 936,983 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 22, 2025 Filed Mar 25, 2025 20:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 19,859 | $10.01 | $198,788.59 |
DisclosureSEC source: 0001628280-25-014723 · wk-form4_1742933780.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 989,665 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 21, 2025. Read SEC document |
| March 15, 2025 Filed Mar 17, 2025 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 30,118 | $10.07 | $303,288.26 |
DisclosureSEC source: 0001628280-25-013139 · wk-form4_1742242739.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,009,524 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 37,564 | $10.07 | $378,269.48 |
DisclosureSEC source: 0001628280-25-013139 · wk-form4_1742242739.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,039,642 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| February 07, 2025 Filed Mar 5, 2025 00:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 114,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010135 · wk-form4_1741134665.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,077,206 F1 · shares: Consists of performance-based restricted stock units (PSUs) initially granted on March 22, 2022, subject to accomplishment of pre-determined performance metrics. On February 7, 2025, the Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025. Read SEC document |
| October 11, 2024 Filed Oct 11, 2024 21:23 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 15,000 | $22.93 | $343,950.00 |
DisclosureSEC source: 0001628280-24-042750 · wk-form4_1728681830.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 962,378 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 11, 2024 Filed Sep 12, 2024 20:11 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 15,000 | $26.72 | $400,800.00 |
DisclosureSEC source: 0001628280-24-040232 · wk-form4_1726171896.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 977,378 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 50,980 | $28.18 | $1,436,616.40 |
DisclosureSEC source: 0001628280-24-037225 · wk-form4_1723667218.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 992,378 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 13, 2024. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 22,808 | $28.18 | $642,729.44 |
DisclosureSEC source: 0001628280-24-037225 · wk-form4_1723667218.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043,358 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 13, 2024. Read SEC document |
| May 15, 2024 Filed May 15, 2024 21:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 75,000 | $25.07 | $1,880,415.00 |
DisclosureSEC source: 0001628280-24-023653 · wk-form4_1715809753.xml · nonDerivative · entry 3 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066,166 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $25.60, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2024 Filed May 15, 2024 21:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 95,000 | $25.21 | $2,394,798.00 |
DisclosureSEC source: 0001628280-24-023653 · wk-form4_1715809753.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,141,166 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.915 to $25.49, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2024 Filed May 15, 2024 21:49 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 57,844 | $25.13 | $1,453,550.31 |
DisclosureSEC source: 0001628280-24-023653 · wk-form4_1715809753.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,236,166 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.83, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 24, 2024 Filed Mar 25, 2024 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 27,233 | $22.24 | $605,661.92 |
DisclosureSEC source: 0001628280-24-012914 · wk-form4_1711398639.xml · nonDerivative · entry 3 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,294,010 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 24, 2024 Filed Mar 25, 2024 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 18,589 | $22.24 | $413,419.36 |
DisclosureSEC source: 0001628280-24-012914 · wk-form4_1711398639.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,321,243 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 20:30 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 20,202 | $22.24 | $449,292.48 |
DisclosureSEC source: 0001628280-24-012914 · wk-form4_1711398639.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,339,832 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2024. Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 20:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 30,610 | $21.16 | $647,707.60 |
DisclosureSEC source: 0001628280-24-011678 · wk-form4_1710794656.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,360,034 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 15, 2024. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 246,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011678 · wk-form4_1710794656.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,390,644 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| August 13, 2023 Filed Aug 14, 2023 20:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 51,292 | $17.89 | $917,613.88 |
DisclosureSEC source: 0001628280-23-029378 · wk-form4_1692044228.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,396 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 11, 2023. Read SEC document |
| August 13, 2023 Filed Aug 14, 2023 20:17 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 22,943 | $17.89 | $410,450.27 |
DisclosureSEC source: 0001628280-23-029378 · wk-form4_1692044228.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,195,688 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 11, 2023. Read SEC document |
| May 15, 2023 Filed May 17, 2023 21:38 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 516 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000139 · wk-form4_1684359474.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,069 Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 26,997 | $23.72 | $640,368.84 |
DisclosureSEC source: 0001628280-23-009258 · wf-form4_167994880541269.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,218,631 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 24, 2023 Filed Mar 27, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 18,428 | $23.72 | $437,112.16 |
DisclosureSEC source: 0001628280-23-009258 · wf-form4_167994880541269.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,245,628 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2023. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 20:27 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 20,046 | $22.91 | $459,253.86 |
DisclosureSEC source: 0001628280-23-009044 · wf-form4_167960325165880.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,264,056 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 22, 2023. Read SEC document |
| March 15, 2023 Filed Mar 16, 2023 20:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 197,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-008321 · wf-form4_167899865022234.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,284,102 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:40 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-23-000055 · wf-form4_167908924066174.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,553 Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 22:29 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 677 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000182 · wf-form4_166863776063047.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,895 Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 23:24 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000145 · wf-form4_166069224738172.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,218 Read SEC document |
| August 13, 2022 Filed Aug 15, 2022 21:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 49,980 | $27.61 | $1,379,947.80 |
DisclosureSEC source: 0001628280-22-022907 · wf-form4_166059671479430.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,087,079 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 12, 2022. Read SEC document |
| August 13, 2022 Filed Aug 15, 2022 21:31 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 22,370 | $27.61 | $617,635.70 |
DisclosureSEC source: 0001628280-22-022907 · wf-form4_166059671479430.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137,059 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 12, 2022. Read SEC document |
| May 15, 2022 Filed May 17, 2022 22:12 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000098 · wf-form4_165282547098815.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,704 Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 20:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 26,200 | $25.32 | $663,384.00 |
DisclosureSEC source: 0000899243-22-012327 · doc4.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,429 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 24, 2022 Filed Mar 25, 2022 20:44 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 17,884 | $25.32 | $452,822.88 |
DisclosureSEC source: 0000899243-22-012327 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,185,629 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 24, 2022. Read SEC document |
| March 22, 2022 Filed Mar 23, 2022 20:43 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 173,144 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011943 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,203,513 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 01:31 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 429 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-22-000028 · wf-form4_164748067380468.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,229 Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:16 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 234,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-007020 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,369 F1 · kind: Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on March 24, 2021, subject to accomplishment of pre-determined performance metrics. On February 16, 2022, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on March 24, 2022, 25% on March 24, 2023, 25% on March 24, 2024, and 25% on March 24, 2025. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:01 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 446 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000178 · wf-form4_163719007307095.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 23:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 49,390 | $34.76 | $1,716,796.40 |
DisclosureSEC source: 0000899243-21-037886 · doc4.xml · nonDerivative · entry 2 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 796,098 F2 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 23, 2021. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 23:39 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 445,439 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-037886 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845,488 F1 · kind: Consists of performance-based restricted stock units (PSUs) initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 23, 2021, the Board of Directors determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on September 23, 2021, and the remaining seventy-five percent (75%) of the earned PSUs will vest in three (3) installments of 25% each on the following dates: August 13, 2022, August 13, 2023, and August 13, 2024. Read SEC document |
| August 15, 2021 Filed Aug 17, 2021 22:33 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 365 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000147 · wf-form4_162923958798272.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,354 Read SEC document |
| August 13, 2021 Filed Aug 16, 2021 23:08 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 58,820 | $32.79 | $1,928,707.80 |
DisclosureSEC source: 0000899243-21-033156 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,049 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on August 13, 2021. Read SEC document |
| May 15, 2021 Filed May 19, 2021 00:20 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 379 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000097 · wf-form4_162138354385917.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,989 Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 21:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 159,915 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-013711 · doc4.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,869 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 21:42 UTC | DAVITA INC. DVA · Entity 3482 | GrantCommon Stock | 436 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-21-000055 · wf-form4_161601732099922.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,610 Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 23:04 UTC | DAVITA INC. DVA · Entity 3482 | GiftCommon Stock | 3,380 | $0.00 | $0.00 |
DisclosureSEC source: 0000927066-20-000262 · wf-form4_160712307139259.xml · nonDerivative · entry 1 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,174 Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:31 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 7,165 | $0.00 Strike: $66.29 | $0.00 |
DisclosureSEC source: 0000927066-20-000259 · wf-form4_160695187731295.xml · derivative · entry 9 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,165 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Appreciation Rights were granted on 5/15/2018. 100% vested on 5/15/2019. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:31 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 7,178 | $0.00 Strike: $66.17 | $0.00 |
DisclosureSEC source: 0000927066-20-000259 · wf-form4_160695187731295.xml · derivative · entry 8 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,178 shares Expires 2022-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Price previously reported as $13.234 on Form 4 filed on 6/20/2017. F3 · derivative.exercise_date: The Stock Appreciation Rights were granted on 6/16/2017. 100% vested on 6/16/2018. Read SEC document |
| November 30, 2020 Filed Dec 2, 2020 23:31 UTC | DAVITA INC. DVA · Entity 3482 | Exercise / conversionStock Appreciation Rights · Derivative | 5,015 | $0.00 Strike: $75.77 | $0.00 |
DisclosureSEC source: 0000927066-20-000259 · wf-form4_160695187731295.xml · derivative · entry 7 DIAZ PAUL J · CIK 0001194247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,015 shares Expires 2021-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Appreciation Rights were granted on 6/20/2016. 100% vested on 6/20/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.